The consensus recommendation by Thomson Reuters analysts is Hold and their mean rating for the stock is 2.77 on scale of 1-5. ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) announced that the Board of Directors has …
IBM
Stock market analysts watching Internap Network Services Corporation (NASDAQ:INAP) have recently changed... ImmunoCellular Therapeutics, Ltd. (IMUC) Reviewed By Analysts Stock market analysts watching …
Analysts Recommend
The stock market indices had a very mixed ... ImmunoCellular Therapeutics, Ltd. (IMUC), after announcing management changes, popped 2.02, or 93%, to 4.20, on 1.4 million shares traded. GenVec, Inc. (GNVC) …
Nasdaq
ImmunoCellular Therapeutics Ltd. (NYSE MKT: IMUC) Get Your Up-To-Date ImmunoCellular Therapeutics …
Neuralstem
The stock has Return on Assets (ROA ... ImmunoCellular Therapeutics, …
Wells Fargo
The stock recently traded at a volume of 0 shares versus average volume of 923.46K. Earnings Roundup: In the last fiscal quarter alone, ImmunoCellular Therapeutics, Ltd. generated almost $480000 in sales and net …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that at the Special Meeting of Stockholders …
Stock
ImmunoCellular Therapeutics price to earnings ratio chart: The stock chart shows IMUC PE ratio for a period of 1 year. As of 16 Dec, 2016, the P/E ratio is 59.13. ImmunoCellular Therapeutics P/E ratio reached a high of …
The recent run of Immunocellular Therapeutics (NYSEMKT:IMUC) nearly reached the two dollar mark on a few occasions last week, and eyes will be on the stock this week to see if that barrier can again be taken down. …
IMUC) announced that at the Special Meeting of Stockholders held on November 14, 2016, ImmunoCellular's stockholders voted to approve a reverse stock split of the Company's issued and outstanding common stock. …
Split